CSF2, colony stimulating factor 2, 1437

N. diseases: 1028; N. variants: 7
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.310 Therapeutic phenotype CTD_human Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF. 14654953 2004
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.310 Biomarker phenotype BEFREE The demonstration of molecular remissions, analysis of cytotoxic T lymphocytes against autologous tumor targets, and addition of granulocyte-monocyte colony-stimulating factor to the vaccine formulation provide principles relevant to the design of future clinical trials of other cancer vaccines administered in a minimal residual disease setting. 10502821 1999